e-learning
resources
Vienna 2009
Monday, 14.09.2009
Biological and clinical markers in lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
W. Naumnik, E. Chyczewska, M. Ossolinska (Bialystok, Poland)
Source:
Annual Congress 2009 - Biological and clinical markers in lung cancer
Session:
Biological and clinical markers in lung cancer
Session type:
Thematic Poster Session
Number:
2661
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Naumnik, E. Chyczewska, M. Ossolinska (Bialystok, Poland). Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy. Eur Respir J 2009; 34: Suppl. 53, 2661
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 82s
Year: 2004
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2002; 20: Suppl. 38, 74s
Year: 2002
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis
Source: Eur Respir J 2001; 18: Suppl. 33, 65s
Year: 2001
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo)
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 771s
Year: 2006
Radiotherapy for stage III non-small cell lung cancer (NSCLC)
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009
Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 463s
Year: 2002
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)?
Source: Eur Respir J 2004; 24: Suppl. 48, 76s
Year: 2004
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007
The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC)
Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept